13), Pseudomonas multivorans (5), Pseudomonas aureofaciens (19) , Pseudomonaspyrrocinia (1) , and Pseudomonas cepacia (12, 18) . The antibiotic substances produced by this group of organisms are numerous, and of these, pyocyanin, pyrrolnitrin, and pseudomonic acid have been produced on a commercial basis (13) . It has been demonstrated that some secondary metabolites produced by pseudomonads confer obvious selective advantages to the producer organisms in their natural environment. For example, the production of phytotoxins enables colonization of specific host plants (15) , slime production by P. aeruginosa enables chest colonization in patients with cystic fibrosis (6, 11) , and production of an antifungal compound by P. cepacia enables colonization of the grass Tripsacum dactyloides (12) . P. aeruginosa, unlike other pseudomonads (1, 5, 12, 18, 19) , has not been shown to possess antifungal properties. The present study was undertaken because of a clinical and laboratory impression that P. aeruginosa suppresses the growth of Candida species in clinically significant chest infections in compromised patients from whom both of these organisms were isolated from serial sputum samples.
Both P. aeruginosa and Candida albicans were isolated from serial sputum samples of three patients. The following information was noted about each of these patients: clinical details, the time that each sputum sample was obtained, relative numbers of each organism isolated from each sputum sample, and time and duration of administration of each antibiotic used in therapy. Only those important clinical details needed for understanding of and affecting the course of infection in each patient were recorded. In each case, the pseudomonads and candidae were identified to the species levels (see below), and susceptibility testing by the method of Stokes and Waterworth (16) To obtain a panel of P. aeruginosa isolates for use in screening for antifungal activity, 10 isolates of P. aeruginosa were collected from routine cultures of sputum. The identities of these and the P. aeruginosa isolates obtained from the three study patients (see above) were confirmed by Gram staining reaction, oxidase production, and the API 20NE system (BioMerieux, la Balme les Grottes, France). All pseudomonal strains were stored at room temperature on nutrient agar slopes (Technical Service Consultants) until the time of the study. At the time of the study, isolates were subcultured to blood agar plates and were checked for purity.
To obtain a panel of fungal strains for use as indicator organisms in the demonstration of antifungal activity by P. aeruginosa, a number of fungi were obtained from the Department of Microbiology and Immunobiology, Mycology Reference Laboratory, Royal Victoria Hospital, Belfast. These were Candida krusei, Candida keyfr, Candida guillermondii, Candida tropicalis, Candida lusitaniae, Candida parapsilosis, Candida pseudotropicalis, C albicans, Torulopsis glabrata, and Saccharomyces cerevisiae. In addition, one strain of Aspergillus fumigatus was also used; this was identified as such by macroscopic and microscopic morphologies. All fungal strains were stored at 4°C on Sabouraud dextrose agar plates until the time of the study. At the time of the study, isolates were subcultured onto fresh Sabouraud dextrose agar plates and were checked for purity.
The method used to test for the antifungal activities of the pseudomonads was similar to that used for pyocin typing of P. aeruginosa (7) . A fresh 24-h plate culture of each Pseudomonas strain to be tested for antifungal activity (i.e., the potential producer strain) was used to prepare an inoculum of 108 CFU/ml in normal saline. Three surgery patients were monitored postoperatively, with particular reference to lung infection. The same pattern was observed in each patient. Initially, each patient received ventilation in an intensive care unit and broad-spectrum antibiotics. At this stage, C. albicans alone was isolated from sputum. Then, when sputum colonization with P. aeruginosa occurred, C. albicans could not be isolated from sputum. However, when antipseudomonal therapy eradicated the pseudomonad, C. albicans was recultured. For each sputum sample, Gram staining was performed prior to culture; C. albicans isolates were not seen in any sample from which they were not also cultured.
Isolates of C. albicans from all three patients were susceptible to fluconazole. Isolates of C. albicans from patients 1 and 2 were susceptible to fluconazole both before and after the start of fluconazole treatment, yet sputum cultures remained positive for the growth of C. albicans. C. albicans was not isolated from patient 3 after the start of fluconazole treatment. Patient 2 died on day 29, and patients 1 and 3 survived beyond the study period; C. albicans was not isolated from the sputum of patients 1 and 3 after the time scale of the study. So, in these patients, fluconazole therapy was associated with the eventual clearance of C. albicans from the sputum. However, in each case this process took a longer amount of time than was expected for a drug to which the target organism was susceptible.
The P. aeruginosa strains isolated from each of the three patients completely inhibited growth of the corresponding C. albicans strain. Table 1 shows the antifungal activities demonstrated by the panel of 10 P. aeruginosa strains against each of the panel of 11 fungi. P. aeruginosa 1, 2, 3, 5, 7, and 8 completely inhibited all the fungi except A. fumigatus, which they partially inhibited. P. aeruginosa 4 showed complete inhibition of C. krusei, C keyfr, C. guillermondii, C. lusitaniae, C. albicans, T. glabrata, and S. cerevisiae; partial inhibition of C. tropicalis, C. parapsilosis, and C. pseudotropicalis; and no inhibition of A. fumigatus. P. aeruginosa 6 showed complete inhibition of C keyfr, C. guillermondii, C. lusitaniae, C. parapsilosis, C. pseudotropicalis, and C. albicans; partial inhibition of C. tropicalis and S. cerevisiae; and no inhibition of C. krusei, T. glabrata orA. fumigatus. P. aeruginosa 9 showed complete inhibition of C. krusei, C. keyfr, C. guillermondii, C. lusitaniae, C. parapsilosis, C. albicans, and T. glabrata; partial inhibition of C. tropicalis, C. pseudotropicalis, and S. cerevisiae; and no inhibition of A. fumigatus. P. aermginosa 10 showed complete inhibition of C. keyfr, C. lusitaniae, C. albicans, T.
glabrata, and S. cerevisiae; partial inhibition of C. (17) , Penicillium species (2, 17), C. albicans (2, 8) , Trichophyton species (2), Aspergillus niger (2), dermatophytes (8), Cryptococcus neoformans (9), Blastomyces dermatitidis (9) , Sporotrichum schenckii (9) , and Histoplasma capsulatum (9) .
Invasion of deep organs by Candida species may complicate the use of broad-spectrum antibiotics (4, 14) . It has been presumed that this is due to alteration of the host's normal flora (14) , allowing the Candida organisms to proliferate. Both C. albicans and P. aeruginosa may be carried by healthy individuals (3, 10) , and because most human infections with Candida species are endogenous, it may be that eradication of coexistent antifungal P. aenuginosa strains by antipseudomonal antibiotics allows fungal proliferation.
It is difficult to draw conclusions about the delayed clearance of C. albicans after the start of fluconazole therapy in patients 1 
